[Activation effects of BCR/ABL antigen on CML T cells mediated by protein transduction domain].
OBJECTIVE
To study the activation effect of BCR/ABL antigen on T cells from CML patients mediated by protein transduction domain (PTD).


METHODS
The fused plasmid containing PTD gene and b3a2 bcr/abl gene of CML was constructed by genetic engineering technique and was expressed in E.coli. The PBMCs from CML patients were stimulated in-vitro with purified PTD-BCR/ABL antigen and then expression of the activation antigen CD25 on CD8(+) and CD4(+) T cells after stimulation was detected by flow cytometry (FCM).


RESULTS
After stimulation with 100 mg/L of PTD-BCR/ABL antigen (final concentration) for 4 days in-vitro, CD8(+) T cells were activated in 5 of 10 CML patients and CD4(+) T cells were activated in 2 of 10 patients. Both CD8(+) and CD4(+) T cells were activated simultaneously in one of them. However, neither CD4(+) nor CD8(+) T cells was activated in BCR/ABL antigen stimulation group as control.


CONCLUSIONS
Using a PTD-mediated antigen transduction system, exogenous BCR/ABL antigen can be transferred into APCs and be processed and presented onto surface of APCs to activate Ag-specific CD8(+) and CD4(+) T cells in-vitro. The strategy outlined in this paper may provide a new approach for priming Ag-specific CD8(+) and CD4(+) T cells in-vitro and immunotherapy of CML.
Liu
Qiang
Q
Department of Hematology of Tangdu Hospital,Fourth Military Medical University, Xi'an 710038,China.
Liang
Ying-Min
YM
Zheng
Jin
J
Li
Xue-Yi
XY
Chen
Ren-An
RA
Jiang
Shan-Shan
SS
Wu
Rong-Li
RL
D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D016827:CD8 Antigens; D018414:CD8-Positive T-Lymphocytes / Q000378:metabolism; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive; D017434:Protein Structure, Tertiary
D016827:CD8 Antigens; D016044:Fusion Proteins, bcr-abl